Zomedica Corp. [ZOM] moved down -2.48: Why It’s Important


Zomedica Corp. [AMEX: ZOM] slipped around -0.01 points on Friday, while shares priced at $0.24 at the close of the session, down -2.48%. The company report on June 15, 2022 that Zomedica to Acquire Assets of Innovative Veterinary Imaging Company Revo Squared.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced it has signed a definitive agreement to acquire substantially all of the assets of Revo Squared LLC (“Revo”).

Revo’s innovative MicroView digital cytology platform will provide veterinarians with best-in-class image quality while providing the first in-clinic automated slide preparation system. Slide preparation is a critical part of cytology, and slide preparation errors are the number one reason cited by pathologists for being unable to read a slide. The MicroView platform improves practice workflow efficiency by automating the process to assure a consistent smear and stain in order to produce a readable slide.

Zomedica Corp. stock is now -21.70% down from its year-to-date (YTD) trading value. ZOM Stock saw the intraday high of $0.24 and lowest of $0.23 per share. The company’s 52-week high price is 0.92, which means current price is +37.14% above from all time high which was touched on 02/17/22.

Compared to the average trading volume of 19.53M shares, ZOM reached a trading volume of 36685644 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Zomedica Corp. [ZOM]?

The Average True Range (ATR) for Zomedica Corp. is set at 0.02, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 30.53. The Price to Book ratio for the last quarter was 0.89, with the Price to Cash per share for the same quarter was set at 0.19.

How has ZOM stock performed recently?

Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.83. With this latest performance, ZOM shares gained by 1.69% in over the last four-week period, additionally sinking by -34.96% over the last 6 months – not to mention a drop of -72.95% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 47.82, with the RSI for the last a single of trading hit 47.36, and the three-weeks RSI is set at 47.24 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.2509, while it was recorded at 0.2396 for the last single week of trading, and 0.3694 for the last 200 days.

Zomedica Corp. [ZOM]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Zomedica Corp. [ZOM] shares currently have an operating margin of -517.14 and a Gross Margin at +46.32. Zomedica Corp.’s Net Margin is presently recorded at -444.78.

Return on Equity for this stock declined to -11.01, with Return on Assets sitting at -10.61.

Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 47.30 and a Current Ratio set at 48.20.

Insider trade positions for Zomedica Corp. [ZOM]

There are presently around $27 million, or 13.40% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 40,607,143, which is approximately -2.47% of the company’s market cap and around 2.56% of the total institutional ownership; STATE STREET CORP, holding 18,717,694 shares of the stock with an approximate value of $4.49 million in ZOM stocks shares; and BLACKROCK INC., currently with $3.22 million in ZOM stock with ownership of nearly 5.57% of the company’s market capitalization.

Positions in Zomedica Corp. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 42 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 4,321,486 shares. Additionally, 42 investors decreased positions by around 15,834,776 shares, while 41 investors held positions by with 93,761,410 shares. The mentioned changes placed institutional holdings at 113,917,672 shares, according to the latest SEC report filing. ZOM stock had 20 new institutional investments in for a total of 1,221,604 shares, while 18 institutional investors sold positions of 2,711,854 shares during the same period.